Clinical Trial Update: Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) [Phase 3]

View source ↗

Summary

Phase 3 trial update for avelumab in first-line maintenance for unresectable, locally advanced or metastatic gastric/GEJ adenocarcinoma (JAVELIN Gastric 100); r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Phase 3 | Status: COMPLETED | Results posted: 2021-11-04